Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1333170/000133317018000002/nxtm20171231-10k.htm
February 2019
January 2019
October 2018
July 2018
July 2018
May 2018
October 2017
October 2017
October 2017
August 2017
Document and Entity Information - USD ($) $ in Billions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2017 | Feb. 08, 2018 | Jun. 30, 2017 | |
Document And Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2017 | ||
Document Fiscal Year Focus | 2017 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | NXTM | ||
Entity Registrant Name | NxStage Medical, Inc. | ||
Entity Central Index Key | 0001333170 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Common Stock, Shares Outstanding | 66,320,683 | ||
Entity Public Float | $ 1.6 |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1333170/000133317018000002/nxtm20171231-10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Nxstage Medical, Inc..
Nxstage Medical, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Rating
Learn More
Increases in net loss after adjustments for non-cash items such as depreciation, amortization and stock-based compensation during 2017 when compared to 2016, driven in part by expenses incurred in connection with the proposed Merger, were offset by improvements in working capital including decreased inventory requirements and timing of accounts receivable collections.
Gross profit as a percentage of revenues for the In-Center segment increased versus 2015 driven primarily by favorable product mix and currency exchange rates.
Cash flow from deferred revenues decreased by $0.2 million during 2017 versus 2016.
Changes in these estimates and assumptions could materially affect the estimated fair values of reporting units and could result in a goodwill impairment charge in a future period.
We also review our inventory value to determine if it reflects the lower of cost or market based on factors such as inventory items sold at negative gross margins and purchase commitments.
Home product revenues increased $15.7...Read more
We believe our procedures for...Read more
The decrease was driven by...Read more
In the event that actual...Read more
We expect In-Center segment revenues...Read more
Also included in this category...Read more
Selling and marketing expenses for...Read more
Included in selling and marketing...Read more
Gross profit as a percentage...Read more
Gross profit as a percentage...Read more
This process involves estimating our...Read more
In aggregate, we expect total...Read more
We expect future demand for...Read more
We expect future demand for...Read more
Selling and marketing expenses for...Read more
Factors we consider important include,...Read more
As of December 31, 2017,...Read more
At the same time, we...Read more
Under these arrangements, revenue is...Read more
General and administrative expenses increased...Read more
We expect general and administrative...Read more
For each of the periods...Read more
As more System One equipment...Read more
Effective January 1, 2018, we...Read more
Revenue from direct product sales...Read more
Revenue from direct product sales...Read more
Revenue from direct product sales...Read more
We expect to sustain gross...Read more
Selling and marketing expenses for...Read more
We expect the adoption of...Read more
Research and development expenses increased...Read more
Research and development expenses increased...Read more
Gross profit as a percentage...Read more
For several years, we have...Read more
For the near term, we...Read more
Revenues are recognized upon delivery...Read more
General and administrative expenses decreased...Read more
Revenues are recognized when: a...Read more
The medical device industry is...Read more
During 2017 and 2016, we...Read more
Over time, as more home...Read more
These items are regularly monitored...Read more
Interest expense decreased $0.1 million...Read more
Critical Care product revenues increased...Read more
Critical Care product revenues increased...Read more
In aggregate, we anticipate that...Read more
Disposable products revenue is recognized...Read more
Distribution expenses increased $3.9 million,...Read more
Distribution expenses increased $2.4 million,...Read more
Selling and marketing expenses consist...Read more
We expect Service segment revenues...Read more
The increase in revenues was...Read more
In-Center segment revenues decreased $1.7...Read more
Our capital lease obligations include...Read more
Disposable product revenues are recognized...Read more
We recognize training and technical...Read more
We enter into multiple-element arrangements...Read more
For the System One equipment...Read more
The plans provide lump sum...Read more
Net cash flows from operating...Read more
We expect gross profit as...Read more
Assessing the impairment of goodwill...Read more
Revenues are recognized based on...Read more
Distribution expenses include the freight...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Nxstage Medical, Inc. provided additional information to their SEC Filing as exhibits
Ticker: NXTM
CIK: 1333170
Form Type: 10-K Annual Report
Accession Number: 0001333170-18-000002
Submitted to the SEC: Fri Feb 16 2018 5:21:12 PM EST
Accepted by the SEC: Fri Feb 16 2018
Period: Sunday, December 31, 2017
Industry: Electromedical And Electrotherapeutic Apparatus